Hanmi Science unit Hanmi Pharmaceutical wins South Korea approval for Epe auto-injector obesity drug
Bitget2026/10/07 10:02Hanmi Science unit Hanmi Pharm won South Korea MFDS marketing authorization for Epe auto-injector (efpeglenatide) obesity drug. Approval covers five strengths, positioning the GLP-1 therapy for chronic weight management in adults alongside diet and exercise. Authorization date: Oct. 7, 2026; filing date: Dec. 17, 2025. Launch preparations underway, targeting domestic supply before year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Science Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007800680), on October 07, 2026, and is solely responsible for the information contained therein.
- Hanmi Science unit Hanmi Pharm won South Korea MFDS marketing authorization for Epe auto-injector (efpeglenatide) obesity drug.
- Approval covers five strengths, positioning the GLP-1 therapy for chronic weight management in adults alongside diet and exercise.
- Authorization date: Oct. 7, 2026; filing date: Dec. 17, 2025.
- Launch preparations underway, targeting domestic supply before year-end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

BUZZ - AI-related stocks rise, boosted by Nvidia’s optimistic outlook

BUZZ - Take-Two shares climb as global launch of Grand Theft Auto VI kicks off